CA
NZ
UK
AU
IND
US
● The confirmed record shows no company-specific release for Scholar Rock during the session.
The FDA is reviewing Savara'sBiologicslicense application for MOLBREEVI, the trade name for molgramostim inhalation solution, under Priority Review, with a target action date of November 22, 2026 following a three-month extension from an original August date. The FDA said the company's responses to recent …
Jefferies lowered its RxSight (NASDAQ:RXST) price target to USD 5.75 per share, continuing a pattern seen across much of 2026 as multiple firms, including UBS, Stifel, Bank of America and Wells Fargo, have repeatedly trimmed their targets following a stretch of sales that missed …
● No confirmed company-specific release was identified for the session.
● No confirmed company-specific news was identified for the session.
● The confirmed record shows no company-specific release tied to Insmed for the session.
● Jaguar Health surged with no company-specific news, press release or filing found to explain the move.
● Johnson & Johnson finished as the third-worst Dow performer, with no company-specific news behind the move.
● The trial enrolled 4,047 adults and compared VAX-31 with Pfizer's Prevnar 20 and Merck's Capvaxive.
● PDS Biotechnology rocketed with aMarket Valueof about $54.2 million, firmly in micro-cap territory.
Please wait processing your request...